

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

### **VOLUNTARY ANNOUNCEMENT –**

### **UPDATE ON INVESTMENT IN AC IMMUNE SA**

This is a voluntary announcement made by Essex Bio-Technology Limited (“**Company**”, together with its subsidiaries, the “**Group**”) to provide the shareholders and potential investors of the Company with an update on its investment in AC Immune SA.

Reference is made to the announcement of the Company dated 11 April 2016 (“**Announcement**”). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the common shares of ACI were successfully listed on The NASDAQ Stock Market of the United States (NASDAQ: ACIU) on 23 September 2016 (“**Listing**”). Upon the Listing, the 518,758 Series E Preferred Shares, which were subscribed by the Group pursuant to the Subscription Agreement, were automatically converted into 518,758 ACI Common Shares. As at the date of this announcement, the Group is interested in approximately 1% of all the ACI Common Shares in issue.

ACI is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. ACI designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. The Board is optimistic about the future performance and growth potential of ACI.

On behalf of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 26 September 2016

*Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.*